Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Analysts at assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPGet Rating) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group cut Titan Pharmaceuticals to a “hold” rating in a research note on Thursday, May 26th.

TTNP opened at $0.58 on Wednesday. The stock’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.88. Titan Pharmaceuticals has a 1 year low of $0.35 and a 1 year high of $3.10.

About Titan Pharmaceuticals (Get Rating)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.

See Also

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with's FREE daily email newsletter.